Exelon Dementia Indication May Revive Flagging Sales, Novartis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of Novartis' Alzheimer's disease therapy Exelon (rivastigmine tartrate) have taken a hit in the U.S. due to increased competition, the company said